Protein balance problems and Alzheimer's-like dementia in Down syndrome

Proteostasis dysregulation and the development of Alzheimer's-like neurodegeneration and dementia in Down syndrome

NIH-funded research Temple Univ of the Commonwealth · NIH-11237975

This project asks whether disrupted protein management in the brain leads to Alzheimer's-like dementia in people with Down syndrome.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionTemple Univ of the Commonwealth NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-11237975 on NIH RePORTER

What this research studies

From the patient's perspective, researchers compare brain samples and markers from people with Down syndrome to those without to see how protein control systems are working. They study a well‑known Down syndrome mouse model (Ts65Dn) to follow early brain changes, measure mTOR pathway activity, and look at signs like amyloid plaques and synaptic loss. The team links biochemical findings to the pattern of neurodegeneration and tests whether correcting proteostasis-related pathways might prevent or slow those changes. Results could point to targets for future treatments aimed at the specific biology of Alzheimer's-like dementia in Down syndrome.

Who could benefit from this research

Good fit: Ideal candidates are people with Down syndrome (or their families) who can provide clinical information, consent to donate samples, or participate in related observational efforts connected to Temple University and collaborators.

Not a fit: People without Down syndrome or those with very advanced dementia unlikely to respond to early-targeted proteostasis interventions may not directly benefit from this work.

Why it matters

Potential benefit: If successful, this work could identify biological targets (like mTOR) that lead to therapies to delay or reduce Alzheimer's-like dementia in people with Down syndrome.

How similar studies have performed: Previous preclinical studies have linked mTOR and proteostasis to Alzheimer's pathology, but applying these findings specifically to Down syndrome is newer and less tested.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.